A Phase Ⅱb Study of XY03-EA Tablets in Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.

Also called NCT06755944

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 360 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06755944
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06755944. Randomized; quadruple masking; primary purpose treatment. Start 2024-12-15 (actual); primary completion 2025-06-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase Ⅱb Study of XY03-EA Tablets in Acute Ischemic Stroke
Acronym
XY03-EA
Condition
Stroke, Ischemic
Intervention (Drug)
XY03-EA 150 mg (per dose)
Intervention (Drug)
XY03-EA 300 mg (Regimen A)
Intervention (Drug)
XY03-EA 300 mg (Regimen B)
Intervention (Drug)
XY03-EA 450 mg (per dose)
Intervention (Drug)
Matching Placebo
Lead sponsor
Shijiazhuang Yiling Pharmaceutical Co. Ltd (class: industry)

Record details

Record id
cardio:ct-nct06755944
Content hash
567d2e0820076d32a62508418e234e4e60906da00ff4c8a937ade0b66458d800